Research graph
References from Predictive value of pre-existing thyroid autoantibodies for PD-1 inhibitor-induced hypothyroidism: a retrospective cohort study. Local targets link to admitted publications; unresolved targets remain external evidence.
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer
10.1001/jamanetworkopen.2020.11818 · 2020 · External reference
Influence of USP15 and its derived-peptide on non-small cell lung cancer immune evasion via regulating PD-L1 stability
10.1136/jitc-2025-014233 · 2026 · External reference
Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
10.3389/fendo.2023.1242830 · 2023 · External reference
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
10.1056/nejmra1703481 · 2018 · External reference
Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
10.3803/enm.2023.1785 · 2023 · External reference
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
10.1210/er.2018-00006 · 2019 · External reference
Immune Related Adverse Events of the Thyroid - A Narrative Review
10.3389/fendo.2022.886930 · 2022 · External reference
Hypothyroidism conversion to hyperthyroidism: it’s never too late
10.1530/edm-18-0047 · 2018 · External reference
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
10.1093/annonc/mdw640 · 2017 · External reference
Predictive value of baseline thyroid autoantibody titers for ICI-associated thyroid adverse events in cancer
10.1530/etj-26-0017 · 2026 · External reference
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
10.1530/etj-24-0328 · 2025 · External reference
Thyroid-related adverse events induced by immune checkpoint inhibitors
10.3389/fendo.2022.1010279 · 2022 · External reference
Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction
10.3389/fendo.2025.1620718 · 2025 · External reference
Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
10.1507/endocrj.ej23-0480 · 2024 · External reference
Incidence of thyroid adverse events following immune checkpoint inhibitor treatment in patients with baseline positive thyroid antibodies: a systematic review and meta-analysis
10.3389/fonc.2025.1583592 · 2025 · External reference
PD-1 Controls Follicular T Helper Cell Positioning and Function
10.1016/j.immuni.2018.06.012 · 2018 · External reference
Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis
10.1126/scitranslmed.adg0675 · 2023 · External reference
Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy
10.1016/j.eprac.2024.07.006 · 2024 · External reference
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
10.1089/thy.2018.0116 · 2018 · External reference
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
10.1053/j.seminoncol.2017.06.002 · 2017 · External reference
Twin studies as a model for exploring the aetiology of autoimmune thyroid disease
10.1111/j.1365-2265.2011.04318.x · 2012 · External reference
Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study
10.1186/s12885-025-15327-x · 2025 · External reference
Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact
10.3390/curroncol33020109 · 2026 · External reference
Effect of iodine intake on thyroid diseases in China
10.1056/nejmoa054022 · 2006 · External reference
Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)
10.1210/jcem.87.2.8182 · 2002 · External reference
The epidemiology of thyroid disease
10.1093/bmb/ldr030 · 2011 · External reference
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer
10.1001/jamanetworkopen.2020.11818 · ExternalCitation · doi-reference
Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy
10.1016/j.eprac.2024.07.006 · ExternalCitation · doi-reference
PD-1 Controls Follicular T Helper Cell Positioning and Function
10.1016/j.immuni.2018.06.012 · ExternalCitation · doi-reference
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
10.1053/j.seminoncol.2017.06.002 · ExternalCitation · doi-reference
Effect of iodine intake on thyroid diseases in China
10.1056/nejmoa054022 · ExternalCitation · doi-reference
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
10.1056/nejmra1703481 · ExternalCitation · doi-reference
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
10.1089/thy.2018.0116 · ExternalCitation · doi-reference
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
10.1093/annonc/mdw640 · ExternalCitation · doi-reference
The epidemiology of thyroid disease
10.1093/bmb/ldr030 · ExternalCitation · doi-reference
Twin studies as a model for exploring the aetiology of autoimmune thyroid disease
10.1111/j.1365-2265.2011.04318.x · ExternalCitation · doi-reference
Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis
10.1126/scitranslmed.adg0675 · ExternalCitation · doi-reference
Influence of USP15 and its derived-peptide on non-small cell lung cancer immune evasion via regulating PD-L1 stability
10.1136/jitc-2025-014233 · ExternalCitation · doi-reference
Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study
10.1186/s12885-025-15327-x · ExternalCitation · doi-reference
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
10.1210/er.2018-00006 · ExternalCitation · doi-reference
Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)
10.1210/jcem.87.2.8182 · ExternalCitation · doi-reference
Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
10.1507/endocrj.ej23-0480 · ExternalCitation · doi-reference
Hypothyroidism conversion to hyperthyroidism: it’s never too late
10.1530/edm-18-0047 · ExternalCitation · doi-reference
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
10.1530/etj-24-0328 · ExternalCitation · doi-reference
Predictive value of baseline thyroid autoantibody titers for ICI-associated thyroid adverse events in cancer
10.1530/etj-26-0017 · ExternalCitation · doi-reference
Thyroid-related adverse events induced by immune checkpoint inhibitors
10.3389/fendo.2022.1010279 · ExternalCitation · doi-reference
Immune Related Adverse Events of the Thyroid - A Narrative Review
10.3389/fendo.2022.886930 · ExternalCitation · doi-reference
Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
10.3389/fendo.2023.1242830 · ExternalCitation · doi-reference
Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction
10.3389/fendo.2025.1620718 · ExternalCitation · doi-reference
Incidence of thyroid adverse events following immune checkpoint inhibitor treatment in patients with baseline positive thyroid antibodies: a systematic review and meta-analysis
10.3389/fonc.2025.1583592 · ExternalCitation · doi-reference
Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact
10.3390/curroncol33020109 · ExternalCitation · doi-reference
Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
10.3803/enm.2023.1785 · ExternalCitation · doi-reference
